News Briefs: CMS Unveils Three Models Aimed at Lowering Drug Costs
-
Feb 16, 2023
CMS on Feb. 14 said the HHS Secretary has chosen three new models for testing by the CMS Innovation Center to help lower prescription drug costs, promote accessibility to life-changing drug therapies, and improve quality of care. The three models selected for testing by the CMS Innovation Center address the themes outlined in President Joe Biden’s executive order on lowering drug costs and meet the selection criteria thresholds of affordability, accessibility, and feasibility of implementation, according to a Feb. 14 press release. First, the Medicare High-Value Drug List Model will encourage Part D plans to offer a low, fixed copayment across all cost-sharing phases of the Part D benefit for a standardized Medicare list of generic drugs that treat chronic conditions. Patients’ out-of-pocket costs for these generic drugs will be capped at a maximum of $2 per month per drug. Under the second model, the Cell and Gene Therapy Access Model, state Medicaid agencies would assign CMS to coordinate and administer multi-state, outcomes-based agreements with manufacturers for certain cell and gene therapies. Finally, under the Accelerating Clinical Evidence Model, CMS would develop payment methods for drugs approved under accelerated approval, in consultation with the Food and Drug Administration, to encourage timely confirmatory trial completion and improve access to post-market safety and efficacy data. This would reduce Medicare spending on drugs that have no confirmed clinical benefit, CMS stated. Read more© 2024 MMIT
![](http://aishealth.mmitnetwork.com/cdn/shop/t/1/assets/blog-ad-img.png?v=91635371509497899061629883494)
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.